Regeneus Ltd. (AU:CMB) has released an update.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Cambium Bio Ltd, a leader in regenerative medicine, reported advances in its Elate Ocular® product for dry eye disease, preparing for Phase 3 trials across Australia, the US, and Taiwan. The company is exploring regulatory fast-track opportunities and strengthening its leadership team, while also seeking additional funding to support its ambitious clinical programs. Despite a cash outflow of $1.5 million last quarter, Cambium Bio remains confident in securing the necessary capital to continue its progress.
For further insights into AU:CMB stock, check out TipRanks’ Stock Analysis page.